» Articles » PMID: 36849190

Heartburn Relief with Bicarbonate-rich Mineral Water: Results of the Randomised, Placebo-controlled Phase-III Trial STOMACH STILL

Overview
Specialty Gastroenterology
Date 2023 Feb 27
PMID 36849190
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: We assessed whether the bicarbonate-rich mineral water Staatl. Fachingen STILL is superior over conventional mineral water in relieving heartburn.

Design: Multicentre, double-blind, randomised, placebo-controlled trial STOMACH STILL in adult patients with frequent heartburn episodes since ≥6 months and without moderate/severe reflux oesophagitis. Patients drank 1.5 L/day verum or placebo over the course of the day for 6 weeks. Primary endpoint was the percentage of patients with reduction of ≥5 points in the Reflux Disease Questionnaire (RDQ) score for 'heartburn'. Secondary endpoints included symptom reduction (RDQ), health-related quality of life (HRQOL, Quality of Life in Reflux and Dyspepsia (QOLRAD)), intake of rescue medication and safety/tolerability.

Results: Of 148 randomised patients (verum: n=73, placebo: n=75), 143 completed the trial. Responder rates were 84.72% in the verum and 63.51% in the placebo group (p=0.0035, number needed to treat=5). Symptoms improved under verum compared with placebo for the dimension 'heartburn' (p=0.0003) and the RDQ total score (p=0.0050). HRQOL improvements under verum compared with placebo were reported for 3 of 5 QOLRAD domains, that is, 'food/drink problems' (p=0.0125), 'emotional distress' (p=0.0147) and 'vitality' (p=0.0393). Mean intake of rescue medication decreased from 0.73 tablets/day at baseline to 0.47 tablets/day in week 6 in the verum group, whereas in the placebo group it remained constant during the trial. Only three patients had treatment-related adverse events (verum: n=1, placebo: n=2).

Conclusion: STOMACH STILL is the first controlled clinical trial demonstrating superiority of a mineral water over placebo in relieving heartburn, accompanied by an improved HRQOL.

Trial Registration Number: EudraCT 2017-001100-30.

Citing Articles

Preparation of a novel antibacterial magnesium carbonate coating on a titanium surface and its biocompatibility.

Xiang S, Zhang C, Guan Z, Li X, Liu Y, Feng G RSC Adv. 2024; 14(15):10516-10525.

PMID: 38567331 PMC: 10985587. DOI: 10.1039/d4ra00399c.


Adapting power calculations to include a superiority margin: what are the implications?.

Bishara S Biochem Med (Zagreb). 2024; 34(1):010101.

PMID: 38361735 PMC: 10864028. DOI: 10.11613/BM.2024.010101.


Non-Chinese herbal medicines for functional dyspepsia.

Baez G, Vargas C, Arancibia M, Papuzinski C, Franco J Cochrane Database Syst Rev. 2023; 6:CD013323.

PMID: 37323050 PMC: 10267606. DOI: 10.1002/14651858.CD013323.pub2.

References
1.
Iwakiri K, Fujiwara Y, Manabe N, Ihara E, Kuribayashi S, Akiyama J . Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022; 57(4):267-285. PMC: 8938399. DOI: 10.1007/s00535-022-01861-z. View

2.
Malfertheiner P, Nocon M, Vieth M, Stolte M, Jaspersen D, Koelz H . Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study. Aliment Pharmacol Ther. 2011; 35(1):154-64. DOI: 10.1111/j.1365-2036.2011.04901.x. View

3.
Aanen M, Numans M, Weusten B, Smout A . Diagnostic value of the Reflux Disease Questionnaire in general practice. Digestion. 2007; 74(3-4):162-8. DOI: 10.1159/000100511. View

4.
Shaw M, Dent J, Beebe T, Junghard O, Wiklund I, Lind T . The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes. 2008; 6:31. PMC: 2390523. DOI: 10.1186/1477-7525-6-31. View

5.
Katz P, Dunbar K, Schnoll-Sussman F, Greer K, Yadlapati R, Spechler S . ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2021; 117(1):27-56. PMC: 8754510. DOI: 10.14309/ajg.0000000000001538. View